{
    "clinical_study": {
        "@rank": "61999", 
        "acronym": "FALCON", 
        "arm_group": {
            "arm_group_label": "0.5 mg Conbercept", 
            "arm_group_type": "Experimental", 
            "description": "patients will receive monthly intravitreal injections of Conbercept to month 3 (total 3 times) and then on an as needed (PRN) dosing schedule based on the pre-specified retreatment criteria till to month 9."
        }, 
        "brief_summary": {
            "textblock": "This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30\n      BRVO and 30 CRVO, respectively) are enrolled in the study. The study included a fixed\n      treatment period (3 months) and a PRN period (6 months). In the fixed treatment period\n      patients will receive 3 consecutive monthly intravitreal of 0.5 mg Conbercept. In the PRN\n      period, patients are monthly visited and retreatment will be needed according to the\n      retreatment criteria pre-specified."
        }, 
        "brief_title": "Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Retinal Vein Occlusion", 
        "condition_browse": {
            "mesh_term": "Retinal Vein Occlusion"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Ability and willingness to provide signed Informed Consent Form.\n\n          2. Age \u2265 18, both male and female\u3002\n\n          3. Ocular Inclusion Criterion (Study Eye):\n\n               -  Diagnosis of Foveal center-involved macular edema due to RVO (both CRVO and\n                  BRVO) within 6 months.\n\n               -  Best corrected visual acuity (BCVA) letter score in the study eye of \u2264\n                  73\uff08Snellen equivalents 20/40\uff09.\n\n               -  Central retinal thickness by OCT in the study eye \u2265 320 \u03bcm.\n\n        Exclusion Criteria:\n\n          1. Brisk afferent pupillary defect.\n\n          2. History of any anti-VEGF treatment in the study and/or system within 6 months before\n             enrollment, and/or in the fellow eye within 3 month.\n\n          3. History of intraocular and/or peri-ocular corticosteroid use in the study eye within\n             3 months, and/or history of use steroids systemic (p.o., i.m., i.v.) within 1 month.\n\n          4. Any active infection involving the ocular including blepharitis, infectious\n             conjunctivitis, keratitis, scleritis, endophthalmitis in either eye.\n\n          5. Any inflammatory cells detected in the anterior chamber and/or vitreous in the study\n             eye.\n\n          6. Presence of non-RVO disease, in the opinion of the investigator, might cause macular\n             edema, such as AMD (wet or dry), diabetes retinopathy, uveitis etc.\n\n          7. Neovascular change in the study eye and/or neovascularization of the iris or\n             neovascular glaucoma in study eye at baseline.\n\n          8. Patients with substantial cataract that, in the opinion of the investigator, is\n             likely to be decreasing visual acuity by equal or more than 3 lines or medicine or\n             surgery treatment are needed in the study eye within 4 months.\n\n          9. Patients diagnosed with systemic immune diseases and any uncontrolled clinical\n             disease.\n\n         10. Pregnant or nursing women.\n\n         11. Patients need to exclude in the opinion of investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01809236", 
            "org_study_id": "KHSWKH902008"
        }, 
        "intervention": {
            "arm_group_label": "0.5 mg Conbercept", 
            "description": "intravitreal injection of 0.5 mg Conbercept", 
            "intervention_name": "Conbercept", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100730"
                    }, 
                    "name": "Beijing Tongren hospital affiliated to Capital Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wenzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "325027"
                    }, 
                    "name": "The Affiliated Eye Hospital of WMC"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Single Arm Clinical Study of Intravitreal Injection of Conbercept in Patients With Maculae Edema Secondary to Retinal Vein Occlusion (the FALCON Study)", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean change from baseline in BCVA", 
            "safety_issue": "No", 
            "time_frame": "3-month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01809236"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean change from baseline in BCVA", 
                "safety_issue": "No", 
                "time_frame": "baseline to 9-month"
            }, 
            {
                "measure": "Mean change from baseline in central retinal thickness", 
                "safety_issue": "No", 
                "time_frame": "baseline to 9-month"
            }, 
            {
                "measure": "Mean injection times", 
                "safety_issue": "No", 
                "time_frame": "baseline to 9-month"
            }, 
            {
                "measure": "Mean change from baseline in Macular edema volume and other anatomical character in the study eye", 
                "safety_issue": "No", 
                "time_frame": "baseline to 9-month"
            }, 
            {
                "measure": "Rate of adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "3-month and 9-month"
            }
        ], 
        "source": "Chengdu Kanghong Biotech Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chengdu Kanghong Biotech Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}